Ignite Creation Date:
2024-05-06 @ 3:31 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04652219
Status:
COMPLETED
Last Update Posted:
2023-07-17
First Post:
2020-11-09
Brief Title:
CART Therapy in GUCY2C-positive Digestive Tract Tumors
Sponsor:
Weijia Fang MD
Organization:
Zhejiang University
Study Overview
Official Title:
Clinical Study on the Safety and Efficacy of CART Cells in the Treatment of Advanced GUCY2C-positive Digestive Tract Tumors
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CART
Brief Summary:
Ict-gc is an open single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors
Detailed Description:
The primary objective of phase 1 is to evaluate the safety of CART regimens The primary objective of phase 2 is to evaluate the efficacy of CART as measured by objective response rate in subjects with colorectal cancer Secondary objectives will include assessing the safety and tolerability of CART and additional efficacy endpoints
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None